Correction to: Blood Cancer Journal (2016) 6, e453; doi:10.1038/bcj.2016.64
The purpose of this corrigendum is to publish grant support omitted in the manuscript 16-BCJ-0175T entitled, ‘Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling defined high-risk multiple myeloma’. Research related to Total Therapy 5 was supported by the P01 Grant awarded to the Myeloma Institute by the National Institutes of Health (P01CA055819).
Additional information
The online version of the original article can be found at 10.1038/bcj.2016.64
Rights and permissions
About this article
Cite this article
Jethava, Y., Mitchell, A., Zangari, M. et al. Erratum: Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myeloma. Blood Cancer Journal 6, e471 (2016). https://doi.org/10.1038/bcj.2016.85
Published:
Issue Date:
DOI: https://doi.org/10.1038/bcj.2016.85
This article is cited by
-
The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
Nature Communications (2022)
-
Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial
Journal of Hematology & Oncology (2019)
